Next Article in Journal
Acknowledgement to Reviewers of Cells in 2017
Next Article in Special Issue
Receptor Tyrosine Kinase Ubiquitination and De-Ubiquitination in Signal Transduction and Receptor Trafficking
Previous Article in Journal
Reagent Tracker Dyes Permit Quality Control for Verifying Plating Accuracy in ELISPOT Tests
Previous Article in Special Issue
Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The “Rotation Model”
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessReview

Targeting FLT3 Mutations in Acute Myeloid Leukemia

King Faisal Specialist Hospital and Research Center Riyadh, Riyadh 11211, Saudi Arabia
*
Author to whom correspondence should be addressed.
Received: 30 October 2017 / Revised: 19 December 2017 / Accepted: 4 January 2018 / Published: 8 January 2018
(This article belongs to the Special Issue Receptor Tyrosine Kinases in Health and Disease)
View Full-Text   |   Download PDF [472 KB, uploaded 10 January 2018]   |  

Abstract

The FMS-like tyrosine kinase 3 (FLT3) pathway has an important role in cellular proliferation, survival, and differentiation. Acute myeloid leukemia (AML) patients with mutated FLT3 have a large disease burden at presentation and a dismal prognosis. A number of FLT3 inhibitors have been developed over the years. The first-generation inhibitors are largely non-specific, while the second-generation inhibitors are more specific and more potent. These inhibitors are used to treat patients with FLT3-mutated AML in virtually all disease settings including induction, consolidation, maintenance, relapse, and after hematopoietic cell transplantation (HCT). In this article, we will review the use of FLT3 inhibitors in AML. View Full-Text
Keywords: FMS-like tyrosine kinase 3; acute myeloid leukemia; Midostaurine FMS-like tyrosine kinase 3; acute myeloid leukemia; Midostaurine
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

El Fakih, R.; Rasheed, W.; Hawsawi, Y.; Alsermani, M.; Hassanein, M. Targeting FLT3 Mutations in Acute Myeloid Leukemia. Cells 2018, 7, 4.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cells EISSN 2073-4409 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top